Patent: 5,821,122
✉ Email this page to a colleague
Summary for Patent: 5,821,122
Title: | Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof |
Abstract: | New tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as NAG tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as NAG coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described. |
Inventor(s): | Guilloux; Yannick (Nantes, FR), Jotereau; Francine (Nantes, FR), Boon-Falleur; Thierry (Brussels, BE), Lucas; Sophie (Brussels, BE), Brichard; Vincent (Brussels, BE) |
Assignee: | Inserm (Institute Nat\'l de la Sante et de la Recherche . .) (Paris, FR) |
Application Number: | 08/487,135 |
Patent Claims: | see list of patent claims |
Details for Patent 5,821,122
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2039-02-26 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2039-02-26 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2039-02-26 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |